Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The blockade of TNF has had significant impact on the therapy of a number of chronic autoimmune diseases. In this chapter we review the concepts leading up to this therapy in rheumatoid arthritis (RA), how it spreads into other autoimmune diseases, and how greater understanding of its use has led to augmented therapeutic benefit. There are still many limitations, but the prospects for the future are intriguing.

Original publication

DOI

10.1016/j.jaut.2005.09.006

Type

Journal article

Journal

Journal of autoimmunity

Publication Date

01/2005

Volume

25 Suppl

Pages

26 - 28

Addresses

Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College, 1 Aspenlea Road, London W6 8LH, UK. m.feldmann@imperial.ac.uk

Keywords

Humans, Arthritis, Rheumatoid, Autoimmune Diseases, Tumor Necrosis Factor-alpha, Cytokines